Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailThe efficacy of medical and surgical treatment of endometriosis-associated infertility: arguments in favour of a medico-surgical aproach
Donnez, Jacques; Chantraine, Frédéric ULg; Nisolle, Michelle ULg

in Human Reproduction Update (2002), 8(1), 89-94

This review discusses the efficacy of a combined, medical (GnRH agonist) and surgical, therapy in endometriosis- associated infertility. Because of the limited information currently available on the ... [more ▼]

This review discusses the efficacy of a combined, medical (GnRH agonist) and surgical, therapy in endometriosis- associated infertility. Because of the limited information currently available on the activity of lesions in minimal and mild endometriosis, any absolute statement is inappropriate at this time, although some arguments exist in favour of treating endometriosis at laparoscopy. In moderate and severe endometriosis, this review provides arguments in favour of a medico-surgical approach and discusses the possibility of combining medical and surgical therapy. [less ▲]

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailEfficacy of monthly oral ibandronate is maintained over 5 years: The MOBILE LTE study.
Felsenberg, D.; Czerwinski, E.; Stakkestad, J. et al

in Osteoporosis International (2009, March), 20(Suppl.1), 15

Detailed reference viewed: 126 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
Miller, P. D.; Recker, R. R.; Reginster, Jean-Yves ULg et al

in Osteoporosis International (2011)

The long-term efficacy and safety of once-monthly ibandronate were studied in this extension to the 2-year Monthly Oral Ibandronate in Ladies (MOBILE) trial. Over 5 years, lumbar spine bone mineral ... [more ▼]

The long-term efficacy and safety of once-monthly ibandronate were studied in this extension to the 2-year Monthly Oral Ibandronate in Ladies (MOBILE) trial. Over 5 years, lumbar spine bone mineral density (BMD) increased from baseline with monthly ibandronate 150 mg (8.4%). Long-term monthly ibandronate is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis. INTRODUCTION: Once-monthly therapy with ibandronate has been studied for up to 5 years in a long-term extension (LTE) to the 2 year MOBILE trial. METHODS: This multicenter, double-blind extension study of monthly ibandronate involved postmenopausal women who had completed 2 years of the MOBILE core study, with >/=75% adherence. Patients were reallocated, or were randomized from daily therapy, to ibandronate 100 mg monthly or 150 mg monthly for a further 3 years. RESULTS: A pooled intent-to-treat (ITT) analysis of 344 patients receiving monthly ibandronate from the core MOBILE baseline showed increases over 5 years in lumbar spine BMD (8.2% with 100 mg and 8.4% with 150 mg). Three-year data relative to MOBILE LTE baseline in the full ITT population of all 698 patients randomized or reallocated from MOBILE (including those previously on daily treatment) showed, on average, maintenance of proximal femur BMD gains achieved in the core 2-year study, with further small gains in lumbar spine BMD. In general, maintenance of efficacy was also indicated by markers of bone metabolism. CONCLUSIONS: There were no tolerability concerns or new safety signals. Monthly treatment with ibandronate 100 and 150 mg is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailEfficacy of nonsteroidal antiinflammatory drugs in postoperative pain
Joris, Jean ULg

in Acta Anaesthesiologica Belgica (1996), 47(3), 115-123

Historically, NSAIDs, used for more than 25 years to treat rheumatologic diseases, were then introduced to relieve pain after tooth extraction, and finally about 10 years ago for postoperative analgesia ... [more ▼]

Historically, NSAIDs, used for more than 25 years to treat rheumatologic diseases, were then introduced to relieve pain after tooth extraction, and finally about 10 years ago for postoperative analgesia. NSAIDs have been increasingly used over the past ten years in the treatment of postoperative pain, such that they now play an important role in the management of postoperative analgesia, either alone or combined with opioids. When used alone, they are effective in relieving minor or moderate pain such as that seen after maxillofacial, minor orthopedic, or some ambulatory surgical procedures, and postpartum pain (episiotomy). In these indications, the main benefit as compared with opioids is the lack of respiratory depression, nausea and vomiting. Since these side effects delay discharge from the hospital after ambulatory surgery, the use of NSAIDs may result in faster recovery and earlier discharge. Because of the ceiling effect of NSAIDs, their efficacy as sole agents is usually insufficient to treat pain after major surgery (orthopedic, abdominal, thoracic). NSAIDs should then be combined with opioids. As part of a balanced analgesia regimen, NSAIDs will allow for opioid-sparing, and might subsequently reduce opioid-mediated side effects. A 20 to 50% reduction in opioid consumption, sometimes with improved quality of analgesia, has been reported using different NSAIDs following various types of surgery. Better respiratory function, improved sleep quality, and faster recovery of gastrointestinal function have been reported with NSAIDs. However, the use of NSAIDs has not been shown to be associated with improved outcome or more rapid recovery. [less ▲]

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy of once-yearly zoledronic acid 5 mg in men with osteoporosis with different levels of serum total testosterone
Boonen, S; Reginster, Jean-Yves ULg; Kaufman, JM et al

in Osteoporosis International (2012, March), 23(S2), 79-80

Detailed reference viewed: 38 (2 ULg)
Full Text
Peer Reviewed
See detailEfficacy of powdered maize cobs against the maize weevil Sitophilus zeamais (Coleoptera: Curculionidae) in stored maize in Senegal
Gueye, Talla Momar; Cissokho, Papa Seyni; Goergen, Georg et al

in International Journal of Tropical Insect Science (2012)

Powdered maize cobs were tested as an alternative for pesticide use in stored maize. Five doses (2, 4, 6, 8 and 10 g/250 g seed) of powdered maize cobs applied at particle sizes of 1.4 and 0.4mm diameter ... [more ▼]

Powdered maize cobs were tested as an alternative for pesticide use in stored maize. Five doses (2, 4, 6, 8 and 10 g/250 g seed) of powdered maize cobs applied at particle sizes of 1.4 and 0.4mm diameter were compared with actellic powder against Sitophilus zeamais Motschulsky for 120 days. Mortality and survival data showed that cob powders did not act as fumigant but exerted a potent inhibition of progeny on direct contact with S. zeamais adults. The particle size of powdered cobs had no effect on maize damage and losses. At doses equal to or higher than 6 g powdered maize cobs/250 g grain maize, i.e. 2.4% (w/w), damage to grain was ,5% and weight losses ,1%. The protection offered at the highest dose was comparable to the pesticide control. The use of powdered maize cobs is discussed as a natural alternative to synthetic pesticides for protection of maize against S. zeamais. [less ▲]

Detailed reference viewed: 43 (2 ULg)
Full Text
Peer Reviewed
See detailEfficacy of pre-ascent climbing route visual inspection in indoor sport climbing
Sanchez, Xavier; Lambert, Philippe ULg; Jones, G. et al

in Scandinavian Journal of Medicine & Science in Sports (2012), 22

Pre-ascent climbing route visual inspection (route preview) has been suggested as a key climbing performance para- meter although its role has never been verified experimentally. We examined the efficacy ... [more ▼]

Pre-ascent climbing route visual inspection (route preview) has been suggested as a key climbing performance para- meter although its role has never been verified experimentally. We examined the efficacy of this perceptual-cognitive skill on indoor sport climbing performance. Twenty-nine male climbers, divided into intermediate, advanced and expert climbing level groups, climbed two indoor sport routes matching their climbing level and, where applicable, routes below their climbing level. At each level, one route was climbed with a preview, where participants benefited from a 3-min pre-ascent climbing route visual inspection. Performance was assessed in terms of output (route comple- tion) and form (number and duration of moves and stops). Route preview did not influence the output performance. Climbers using visual inspection were no more likely to finish the ascent than those without the option of using visual inspection. Conversely, route preview did influence form performance; climbers made fewer, and shorter stops during their ascent following a preview of the route. Form performances differences remained when baseline ability levels were taken into account, although for shorter duration of stops only with expert climbers benefiting most from route preview. The ability to visually inspect a climb before its ascent may represent an essential component of performance optimization. [less ▲]

Detailed reference viewed: 32 (4 ULg)
Full Text
Peer Reviewed
See detailEfficacy of quetiapine in treatment-resistant panic disorder: a case report.
PITCHOT, William ULg; Ansseau, Marc ULg

in Asian Journal of Psychiatry (2012), 5(2), 204-205

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
Delmas, P. D.; Ensrud, K. E.; Adachi, J. D. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(8), 3609-3617

The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999):6371. This report assesses the ... [more ▼]

The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999):6371. This report assesses the efficacy of raloxifene on the long-term cumulative incidence new vertebral fractures through 4 yr. New vertebral fractures was assessed from radiographs taken at baseline, yr 2-4. The primary analysis was the cumulative incidence of new vertebral fractures through 4 yr. A posthoc analysis compared the vertebral fracture risk in yr 4 alone with that observed in the first 3 yr. The 4-yr cumulative relative risks (RR) for one or more new vertebral fractures were 0.64 [95% confidence interval (CI) 0.53, 0.761 with raloxifene 60 mg/d and 0.57 (95% CI 0.48, 0.69) with raloxifene 120 mg/d. In yr 4 alone, raloxifene 60 mg/d reduced the new vertebral fracture risk by 39% [RR 0.61 (95% CI 0.43,0.88)], which was not found to be significantly different from the RR observed in the first 3 yr in both raloxifene groups, irrespective of prevalent fracture status. The nonvertebral fracture risk was not significantly reduced [RR 0.93 (95% CI 0.81, 1.06)]. The safety profile after 4 yr was similar to that observed after 3 yr. Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis. The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailEfficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.
Vanstraelen, Gaetan; Baron, Frédéric ULg; Frere, Pascale ULg et al

in Haematologica (2005), 90(9), 1269-70

On day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment ... [more ▼]

On day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment (control group). After 3 weeks, hemoglobin (p<0.0001) and serum transferrin receptor (p<0.0001) concentrations were higher in the Epo group. Hb response (+2 g/dL) was achieved in 100% vs 28% (p<0.0001) and Hb correction (> or =13 g/dL) in 70% vs 10% (p=0.0238) of the patients, respectively. This is the first randomized study showing an efficacy of erythropoietin therapy on Hb levels after autologous PBSCT. [less ▲]

Detailed reference viewed: 46 (3 ULg)
Full Text
Peer Reviewed
See detailEfficacy of risedronate in decreasing the incidence of femoral neck and intertrochanteric fractures in older women with osteoporosis
Eastell, R; McClung, MR; Reginster, Jean-Yves ULg et al

in Journal of Bone and Mineral Research (2001), 16(S1), 219

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailThe efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Kopylov, U.; Mantzaris, G. J.; Katsanos, K. H. et al

in Alimentary Pharmacology & Therapeutics (2011), 33(3), 349-57

Background Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing ... [more ▼]

Background Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks. Aim We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-doubling. Methods This work was a multicentre retrospective study of infliximab-treated CD patients who required dose escalation. The clinical outcome of patients treated by intensification to 5 mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks). Results Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-week group and 39 (41%) in the double-dose group. Demographics and disease characteristics were similar between the two groups, although patients with re-emerging symptoms 5-7 weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-week group and 67% in the double-dose group (P = N.S.). Regained response was maintained for 12 months in 40% compared with 29% of the patients respectively (P = N.S.). Conclusion In CD patients who lost response to standard infliximab dose, especially when symptoms re-emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 4 weeks. [less ▲]

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailEfficacy of Sublingual Lorazepam Versus Intrarectal Diazepam for Prolonged Convulsions in Sub-Saharan Africa.
Malu, Celestin Kaputu Kalala; Kahamba, Daniel Mukeba; Walker, Timothy David et al

in Journal of child neurology (2013)

In Sub-Saharan Africa, intrarectal diazepam is the first-line anticonvulsant mostly used in children. We aimed to assess this standard care against sublingual lorazepam, a medication potentially as ... [more ▼]

In Sub-Saharan Africa, intrarectal diazepam is the first-line anticonvulsant mostly used in children. We aimed to assess this standard care against sublingual lorazepam, a medication potentially as effective and safe, but easier to administer. A randomized controlled trial was conducted in the pediatric emergency departments of 9 hospitals. A total of 436 children aged 5 months to 10 years with convulsions persisting for more than 5 minutes were assigned to receive intrarectal diazepam (0.5 mg/kg, n = 202) or sublingual lorazepam (0.1 mg/kg, n = 234). Sublingual lorazepam stopped seizures within 10 minutes of administration in 56% of children compared with intrarectal diazepam in 79% (P < .001). The probability of treatment failure is higher in case of sublingual lorazepam use (OR = 2.95, 95% CI = 1.91-4.55). Sublingual lorazepam is less efficacious in stopping pediatric seizures than intrarectal diazepam, and intrarectal diazepam should thus be preferred as a first-line medication in this setting. [less ▲]

Detailed reference viewed: 17 (3 ULg)
Peer Reviewed
See detailEfficacy of Sustained-Release Vaginal Oestriol in Alleviating Urogenital and Systemic Climacteric Complaints
Foidart, Jean-Michel ULg; Vervliet, J.; Buytaert, Ph

in Maturitas (1991), 13(2), 99-107

In a double-blind, placebo-controlled study, 109 patients suffering from local and vasomotor postmenopausal complaints were randomly assigned to treatment with either depot vaginal suppositories ... [more ▼]

In a double-blind, placebo-controlled study, 109 patients suffering from local and vasomotor postmenopausal complaints were randomly assigned to treatment with either depot vaginal suppositories containing 3.5 mg oestriol (E3) or a placebo. The treatment schedule comprised one vaginal suppository twice weekly for 3 weeks initially, followed by maintenance therapy with one vaginal suppository weekly for the 6-month study period. The effectiveness of the therapy was assessed on the basis of questionnaires (Kupperman index for vasomotor complaints and an original urogenital index for local complaints) and gynaecological examinations which included assessments of vaginal cytology, vaginal pH and Doderlein bacilli. To rule out induced endometrial proliferation, endometrial biopsies were performed in 50 women before and after the study. The vaginal depot (E3) formulation showed highly significant superiority over the placebo with respect to therapeutic effect on local urogenital complaints and alleviation of vasomotor complaints, including hot flushes. Analysis of the endometrial biopsies indicated that the monotherapy used caused no endometrial stimulation. Taking into account the minimal rate of adverse effects, the 3.5 mg E3 depot formulation studied represents a useful variant in the range of preparations available for the treatment of post-menopausal complaints. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailEfficacy of the metaflumizone-amitraz association in a case of canine straelensiosis (Straelensia cynotis)
Franc, A.; Mignon, Bernard ULg

in Annales de Médecine Vétérinaire (2011), 155

Detailed reference viewed: 25 (5 ULg)
Full Text
Peer Reviewed
See detailEfficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Caron, Ph; Beckers, Albert ULg; Cullen, C. R. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(1), 99-104

Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this ... [more ▼]

Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 +/- 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 +/- 0.22 ng/ml) and IGF-I (317 +/- 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 +/- 0.19 ng/ml; IGF-I, 323 +/- 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy. [less ▲]

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailThe Efficacy of Two Vaccination Schemes against Experimental Infection with a Virulent Amyxomatous or a Virulent Nodular Myxoma Virus Strain
Marlier, Didier ULg; Mainil, Jacques ULg; Boucraut-Baralon, C. et al

in Journal of Comparative Pathology (2000), 122(2-3, Feb-Apr), 115-22

Two types of myxomatosis vaccine are available commercially, namely, vaccine prepared from the Shope fibroma virus (SFV) and that prepared from an attenuated myxoma virus (MV) strain, e.gSG33. An ... [more ▼]

Two types of myxomatosis vaccine are available commercially, namely, vaccine prepared from the Shope fibroma virus (SFV) and that prepared from an attenuated myxoma virus (MV) strain, e.gSG33. An experiment was designed to compare two vaccination schemes for their ability to protect rabbits against challenge with either a virulent amyxomatous MV strain or a virulent nodular MV strain. Apart from a difference in the cutaneous expression of the disease, the two challenge strains resembled each other in respect of mortality rate, naso-conjunctival shedding of virus, and tissue infection. Vaccination with SFV alone failed to prevent clinical signs, naso-conjunctival shedding or tissue infection. Vaccination with SFV followed by a booster inoculation with SG33 protected rabbits against the development of clinical signs and significantly reduced both viral shedding in naso-conjunctival exudates and viral infection of eyelids, lungs and testes; virus was, however, isolated from testes of some surviving animals. [less ▲]

Detailed reference viewed: 25 (3 ULg)
Peer Reviewed
See detailEfficacy of upper urinary tract stones treatment by ESWL under local anesthesia, with the use of the Dornier Compact alpha Lithotriptor.
Leduc, frédéric; Ben Younes, Adelin; Andrianne, Robert ULg et al

Poster (2002, September)

Detailed reference viewed: 58 (5 ULg)
Peer Reviewed
See detailEfficience et bilan de l'azote apporté par l'engrais et par les eaux usées traitées.
Khelil, M. N.; Rejeb, S.; Destain, Jean-Pierre ULg et al

Conference (2003, September)

Detailed reference viewed: 26 (1 ULg)